Q-omics provides the consensus-scored TXNDC15 profile across patient tissues and cancer cell-line models. TXNDC15 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, TXNDC15 is differentially expressed in 12, with the highest sampling consensus in KIRC. Additionally, TXNDC15 RNA expression shows 20,884 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRC, and UVM as cancer lineages where TXNDC15 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TXNDC15 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TXNDC15 survival associations across molecular data types. TXNDC15 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (6) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TXNDC15 RNA expression–survival associations across cancer types. High TXNDC15 expression shows unfavorable associations in SCLC, UVM, LGG and KIRP, but favorable associations in KIRC and LUAD. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for TXNDC15 RNA expression.
This table summarizes TXNDC15 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 6. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for TXNDC15. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TXNDC15 shows lower tumor expression in THCA, KICH, LUSC and BLCA and higher tumor expression in KIRC and LIHC. The KIRC box plot shows higher TXNDC15 RNA expression in tumor versus normal tissue (log2 FC = +0.725, t-test p < 0.001).
This table shows molecular features associated with TXNDC15 in patient tissues and cancer cell lines. In patient samples, TXNDC15 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, TXNDC15 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in OVARY and UPPER_AERODIGESTIVE_TRACT.
